Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms …
M Hans, Y Zhou, L O'Loughlin Kieran… - Cancer Chemotherapy …, 2007 - search.proquest.com
Purpose The proteasome inhibitor bortezomib may be effective in combination with
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of …
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of …
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms …
H Minderman, Y Zhou, KL O'Loughlin… - Cancer chemotherapy and …, 2007 - Springer
Purpose The proteasome inhibitor bortezomib may be effective in combination with
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of …
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of …
Proteasome inhibitor bortezomib overcomes P‐gp‐mediated multidrug resistance in resistant leukemic cell lines
B Zheng, R Zhou, Y Gong, X Yang… - International journal of …, 2012 - Wiley Online Library
Introduction: To study the effect of bortezomib alone or in combination with daunorubicin
(DNR) on an mdr1 single‐factor drug‐resistant leukemia cell line K562/MDR1, a multifactor …
(DNR) on an mdr1 single‐factor drug‐resistant leukemia cell line K562/MDR1, a multifactor …
The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype
E Colado, S Álvarez-Fernández, P Maiso, J Martín… - 2008 - digital.csic.es
[Background]: Proteasome inhibition represents a promising novel anticancer therapy, and
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …
Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia
L Gil, J Styczynski, D Dytfeld, R Debski… - Anticancer …, 2007 - ar.iiarjournals.org
Background: Bortezomib is an inhibitor of proteasome and NF-κB, with activity in various
solid tumors and hematological malignancies. Aim: The aim of the study was the analysis of …
solid tumors and hematological malignancies. Aim: The aim of the study was the analysis of …
Preclinical Studies on the Molecular Basis of Bortezomib Resistance and Modalities to Overcome Resistance in Hematological Malignancies
J Cloos, D Niewerth, G Jansen - Resistance to Proteasome Inhibitors in …, 2014 - Springer
The success of the proteasome inhibitor bortezomib for the treatment of multiple myeloma
has encouraged its broader use for other hematological malignancies such as lymphomas …
has encouraged its broader use for other hematological malignancies such as lymphomas …
The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-κB pathway
H Wang, X Wang, Y Li, A Liao, B Fu… - Die Pharmazie-An …, 2012 - ingentaconnect.com
Multi-drug resistance (MDR) is one of the obstacles for leukemia therapy, the major cause is
an overexpression of P-glycoprotein (P-gp) leading to increased drug efflux. We investigated …
an overexpression of P-glycoprotein (P-gp) leading to increased drug efflux. We investigated …
Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins
A Pigneux, FX Mahon, F Moreau-Gaudry… - Cancer biology & …, 2007 - Taylor & Francis
Proteasome inhibitors are a novel class of compounds that might increase sensitivity to
chemotherapy for acute myeloid leukemia (AML). We quantified apoptosis in THP-1 cells …
chemotherapy for acute myeloid leukemia (AML). We quantified apoptosis in THP-1 cells …
[HTML][HTML] Phase II study of bortezomib, mitoxantrone and etoposide in relapsed/refractory acute leukemias
J Filicko-O'Hara, B Mookerjee, O Alpdogan, EC Besa… - Blood, 2010 - Elsevier
Abstract 2192 Bortezomib is a proteasome inhibitor known to affect multiple signaling
pathways., The inhibition of nuclear factor KB (NF-KB) activation and the induction of …
pathways., The inhibition of nuclear factor KB (NF-KB) activation and the induction of …
[HTML][HTML] Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
YX Wu, JH Yang, H Saitsu - Oncotarget, 2016 - ncbi.nlm.nih.gov
Bortezomib (BTZ), a proteasome inhibitor, is the first proteasome inhibitor to be used in
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …